Aurora Cannabis Stock (TSX: ACB) (NYSE: ACB) - Investor Dashboard


Aurora Cannabis
TSX: ACB
NYSE: ACB
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: >1400 as of 9/2018
Established: 2013
CEO: Terry Booth

Summary

Fiscal Year-End: June 30
Licensed Facilities: 11
Dried Flower: Production and Sale
Extracts: Production and Sale
Number of Patients: 67,484 at 9/30/18
Headquarters: Vancouver, BC

Financials (09/30/18)

Cash on hand: $147.8mm
Fixed Investment: $449.9mm
Shareholders’ Equity: $4.40 billion
Revenues – Last Quarter: $29.7mm
Adj. Gross Margin: 67.8%
EPS : $0.12

Capital Structure (11/09/18)

Last Equity Fin: $230mm Convertible Notes at $13.05
Basic Shares: 965.1mm
Warrants: 22.6mm
Options: 42.2mm
Diluted Shares: 1049.6mm

Company Brief

Aurora is one of the world’s largest and fastest growing cannabis companies. Following the acquisition of MedReleaf, the company has more than 1,200 employees, 11 facilities, and a funded annual production capacity of more than 500,000 kilograms. The company advanced its vertical integration strategy with the acquisition of cannabis biotechnology company Anandia Laboratories. Aurora has created a growing constellation of subsidiaries and strategic partnerships that provide differentiation in terms of geographic reach, production, technology, product offering, and execution.

With a growing number of countries adopting medical cannabis legislation, the Company has embarked on an aggressive international expansion strategy that currently sees Aurora with operations and/or sales and participation across five continents.

Featured Video

Cam Battley, CCO of Aurora Cannabis, speaks with Cannabis Editor, Mark Rendell, about his company’s ambition and partnership deals and explains that the cannabis industry is “a bit like a land grab”.


Differentiators

Canadian Operations

  • Multiple state-of-the-art facilities in operation or under construction:
    • Alberta: Aurora Sky, Aurora MTN, and Aurora Sun
    • Saskatchewan: CanniMed (acquired in 2018)
    • Quebec: Aurora VIA and H2 Biopharma
    • Ontario: MedReleaf (pending $2.51 billion acquisition)
  • Acquisition of MedReleaf brings the company’s annual production capacity up to 570,000 kilograms through nine facilities in Canada in and two in Europe
  • All products certified by testing through Anandia Laboratories
  • Acquisition of Anandia Laboratories gives the company access to new revenue streams including tissue culture archiving, genetic testing, and predictive chemotype profiling
  • Only LP with tissue micro-propagation lab
  • Unique Temple strain with CBD tested at 24%
  • Ownership of CanvasRx, the largest operator of cannabis clinics in Canada with 35 clinics open
  • Same-day delivery in Alberta and innovative mobile ordering app
  • Supply agreements with 12 provinces and territories
  • Agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart to distribute and sell medical cannabis
  • Strong product portfolio with Aurora, CanniMed, and MedReleaf brands and wellness brands including San Rafael ’71, Woodstock, and AltaVie
  • 40 clinical studies completed or ongoing
  • Vertically integrated with a large private alcohol retailer

Global Operations

  • Active in five continents and 20 countries
  • 22.9% ownership of Australia’s Cann Group (ASX: CAN)
  • Ownership of German distribution company Pedanios
  • 51% ownership of Aurora Nordic in Denmark
  • Medical cannabis supply agreement with the Italian government
  • Approved for the first cannabis cultivation facility in Malta
  • Acquired European hemp company Agropro and sister company Borela
  • 22.9% investment in Austrailian company Cann Group
  • Supply agreement in South Africa
  • Import permit from the Polish Ministry of Health
  • Large investment portfolio including TGOD, Radient Technologies, Hempco, Alcanna (formerly Liquor Stores N.A.), and more


Institutional Analyst Coverage

NEIL MARUOKA
Canaccord

MARTIN LANDRY
GMP Securities

JASON ZANDBERG
PI Financial

GREG MCLEISH, CFA
Mackie Research


Curated Stories & News


Visit Aurora Cannabis
at www.auroramj.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Aurora Cannabis is a client of NCV Media, LLC. Read our full disclaimer.